More than 500 members of the myasthenia gravis (MG) rare disease community will come together this week in-person and ...

Sunshine Cruz recently revealed that she’s battling an autoimmune disease called myasthenia gravis. In an Instagram post, the ...

Analysts were happy with batoclimab’s performance in the chronic autoimmune disorder, but Immunovant said it will continue to ...

The companies reported Wednesday that batoclimab showed improvements in myasthenia gravis patients in a Phase 3 trial.

In the coming two weeks, the FDA is expected to announce three big decisions, including one for a dry eye disease therapy.

Switching to IMVT-1402 extends the head starts Immunovant has already ceded to its rivals. Argenx won FDA approval for ...

Interim data from phase 2 KYSA-6 study, using KYV-101 for the treatment of patients with Myasthenia Gravis, expected 2nd half ...

Nkarta is laying off a third of its employees, including half of the biotech’s executive leadership, as the company diverts ...

This CME program is designed to enhance neurologists' understanding and management of generalized myasthenia gravis (gMG). Participants will explore how comprehensive assessment of disease burden ...

Rozanolixizumab is a high-affinity humanized immunoglobulin G4 monoclonal antibody and Fc receptor blocker approved to treat ...

Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients.